We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Genetic Markers of Coronary Heart Disease in Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00078052
Recruitment Status : Completed
First Posted : February 19, 2004
Last Update Posted : March 20, 2013
Information provided by (Responsible Party):

February 17, 2004
February 19, 2004
March 20, 2013
September 2003
August 2008   (Final data collection date for primary outcome measure)
cardiovascular disease [ Time Frame: 1990-2006 ]
Not Provided
Complete list of historical versions of study NCT00078052 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Genetic Markers of Coronary Heart Disease in Type 2 Diabetes
Not Provided
To investigate genetic markers of coronary heart disease in type 2 diabetes.


Coronary heart disease (CHD), as the leading cause of death in the United States, is of significant public health concern. Despite the knowledge that atherosclerosis is the underlying cause of CHD, the recognition that both genetic and environmental factors contribute to the occurrence of disease, and the identification of a large number of genetic and environmental factors that have been found to be associated with disease risk, the etiology of atherosclerosis with the later development CHD continues to be not very well understood.


The nested case-control study will determine whether variability in 20 genes belonging to endothelial and inflammatory dysfunction pathways is related to the risk of coronary heart disease (CHD) among men and women diagnosed with type 2 diabetes in two large ongoing prospective studies, the Nurses' Health Study (NHS) and Health Professionals' Follow-up Study (HPFS). This will be accomplished by combining two complementary approaches that are made possible by the recent advances in knowledge of the human genome and high-throughput genotyping technologies. The investigators will directly target functional variants in the coding regions of the candidate genes and also investigate the association between CHD and ancestral haplotypes at each locus. The specific aims are: 1. To identify novel variants in 10 candidate genes of the inflammatory, and endothelial dysfunction pathways that have not been systematically screened for polymorphisms by targeted resequencing; 2. To assess the relationship between functional variants in 20 candidate genes in the inflammatory and endothelial dysfunction pathways and risk of CHD among subjects with diabetes of the NHS and HPFS cohorts; 3. To identify the subset of polymorphisms that best capture the overall genetic variability at each locus (haplotype tagging single nucleotide polymorphisms (SNPs) or htSNPs) and investigate the association between CHD risk and the haplotypes defined by these htSNPs; 4. To examine individual SNPs as well as haplotypes in relation to biochemical markers of inflammation and endothelial activation such as CRP, ICAM-1, VCAM-1, E-selectin, and TNF-a in diabetic individuals; and 5. To examine gene-environment interactions in relation to CHD risk in diabetic subjects. By 2006, an estimated 820 cases of CHD will have been confirmed among diabetic men and women in the blood cohorts. The large size, prospective design, high follow-up rates, detailed and reliable long-term lifestyle and outcome information, and the availability of blood specimens make these cohorts a valuable and unique resource for studying genetic determinants of accelerated atherosclerosis in diabetic patients.

Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Plasma and buffy coat
Non-Probability Sample
Nurses' Health Study and Health Professionals' Follow-up Study
  • Cardiovascular Diseases
  • Coronary Disease
  • Diabetes Mellitus, Non-insulin Dependent
  • Diabetes Mellitus
  • Heart Diseases
Not Provided
Not Provided
Ma X, Bacci S, Mlynarski W, Gottardo L, Soccio T, Menzaghi C, Iori E, Lager RA, Shroff AR, Gervino EV, Nesto RW, Johnstone MT, Abumrad NA, Avogaro A, Trischitta V, Doria A. A common haplotype at the CD36 locus is associated with high free fatty acid levels and increased cardiovascular risk in Caucasians. Hum Mol Genet. 2004 Oct 1;13(19):2197-205. Epub 2004 Jul 28. Erratum in: Hum Mol Genet. 2005 Dec 15;14(24):3973.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
August 2008
August 2008   (Final data collection date for primary outcome measure)
no history of CVD or cancer at baseline
Sexes Eligible for Study: All
Child, Adult, Senior
Contact information is only displayed when the study is recruiting subjects
Not Provided
5R01HL071981-04 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Not Provided
Frank B. Hu, Harvard School of Public Health
Harvard School of Public Health
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Frank Hu Harvard School of Public Health
Harvard School of Public Health
March 2013